GWAS studies of autoimmune disorders have yielded hundreds of replicated associations, but moving from genetic association to functional studies with potential clinical relevance is a challenge. Leveraging GWAS data, Lee et al. now identify FOXO3 activity as predictive of disease severity in Crohn's disease and rheumatoid arthritis as well as malaria, likely by acting through regulation of cytokine production in monocytes.
The deluge of GWAS publications over the last several years have provoked concern that the generally very modest effect sizes of the associations will be difficult to translate into meaningful insights into disease mechanisms, let alone provide useful diagnostic markers. Nevertheless, in the case of autoimmune diseases, GWASs have been particularly fruitful in terms of identifying large numbers of reproducible associations and have revealed intriguing overlaps between different autoimmune disorders that involve both the innate and adaptive immune systems (Cho and Gregersen, 2011) . While coding region variants with defined effects on immune function have been identified, many GWAS associations appear to involve regulatory functions that can be tied to quantitative immune traits (Gregersen et al., 2012) . The report by Lee et al. (2013) in this issue of Cell provides a beautiful integration of genetic, clinical, and functional data in mouse and human to shed light on the pathway influenced by such a noncoding SNP. The study also extends the application of GWAS to encompass genetic influences on disease outcome, independent of the usual focus on disease susceptibility.
The current report begins with a focus on genes related to IL7 and IL2 signaling pathways that were previously shown to vary in expression patterns according to disease prognosis in Crohn's disease, systemic lupus and vasculitis (McKinney et al., 2010) . By focusing on these pathways and limiting the analysis to 1,134 SNPs in 81 genes, the authors mitigated the requirement for stringent statistical significance generally demanded for GWAS studies; nevertheless they met this standard (p < 5 3 10 À8 ) by performing replication studies. Several genes in the IL7 and IL2 pathways are associated with disease susceptibility, but none of these influenced disease outcome. In contrast, a strong correlation with disease outcome was observed for the singlenucleotide variant rs12212067, in the FOXO3 locus, which has not been previously associated with risk for human autoimmune disorders. FOXO3 is a member of the FOXO family of transcription factors, most of which are widely expressed and regulate diverse cellular programs including cell-cycle control, DNA repair, and response to oxidative stress (Hedrick, 2009) , with a potential impact on longevity. FOXO3 in particular has also been previously implicated in more specialized immune regulatory functions in macrophages (Litvak et al., 2012) , dendritic cells, and T cells (Dejean et al., 2009 ). Thus it is not entirely surprising that this gene might regulate the expression of human immune and inflammatory disease phenotypes. Using a local resource of genotyped healthy controls, Lee et al. went on to show that a haplotype containing the minor allele (G) of rs12212067 was associated with higher transcription of FOXO3 in blood monocytes, but only after stimulation with lipopolysaccharide (LPS). Moreover, the minor (G) allele at FOXO3 downregulates the production of TNF and several other proinflammatory cytokines in response to LPS and other toll-like receptor 4 (TLR) ligands. In contrast, IL10, a cytokine that is associated with anti-inflammatory effects, is upregulated by the minor allele in response to TLR stimulation. These results are consistent with the more indolent disease course that was observed in Crohn's disease patients who carry this haplotype. FOXO3 is exported out of the nucleus after cell activation, and, in a further surprising twist to this story, a more rapid time course of nuclear reaccumulation of FOXO3 was associated with the minor (G) allele. The time-dependent effects of these events on cytokine production were mediated by TGFb. Further experiments suggested direct regulation of TGFb by FOXO3 itself, although other mechanisms may also account for the TGFb dependent anti-inflammatory effects on monocyte function.
It is important to emphasize that all of these functional studies were carried out in human cells by taking advantage of the Cambridge Bioresource. This is an invaluable collection of healthy volunteers who can be recalled for functional studies on the basis of their genotype, and this resource supported some of the first functional studies of GWAS associations in autoimmunity (Dendrou et al., 2009) . Without this population resource, a convincing connection between FOXO3 genotype and phenotype would be difficult to establish, because studies of Crohn's patients would be confounded by disease activity and therapy, and functional studies in cell lines may not reflect the situation in native cells. Lee et al. provide supporting data in FOXO3-deficient mice, showing more severe disease activity in a colitis model, but overall the most compelling mechanistic data supporting the human genetic findings come from studies in native human cells.
The identification of laboratory predictors of individual variation in disease outcome and response to therapy is the holy grail of personalized medicine. Progress has been tangible in the area of oncology, where the molecular taxonomy of the tumor is prognostically informative and is driving selection of therapy (McCarthy et al., 2013) . In contrast, progress has been slow in developing useful biomarkers in autoimmune and inflammatory disorders. Lee et al. provide evidence for some prognostic value for FOXO3 in progression and severity not only in Crohn's disease but also for rheumatoid arthritis and malaria. Satisfyingly, the minor allele SNP was associated with a less dire outcome in rheumatoid arthritis, similar to Crohn's, as would be predicted for an autoimmune disease, whereas the same variant was associated with a more severe course of malaria infection as might be predicted for an infectious disease relying on cytokine-mediated pathogen clearance. It will be of great interest to whether the prognostic utility of FOXO3 genotype can be confirmed in larger studies. This may be correlated with the TGFb dependent phenotypes in monocytes defined by Lee et al. or with other immune cell phenotypes. One of the major barriers to these studies is the absence of large cohorts with well-characterized disease outcome as part of the phenotype because most large collections have been assembled to address the issue of disease susceptibility. For example, studies of response to TNF inhibition in rheumatoid arthritis have been very disappointing in part because of lack of high-quality, prospectively collected data on disease activity and progression. Failure may also be related to the exclusively univariate approaches to analysis. In this regard, a recent crowd sourcing initiative to examine genetic predictors of drug response in RA may generate more insights (Plenge et al., 2013) .
The incorporation of GWAS data into the larger universe of basic biology, network analysis, and clinical data is an exciting, if daunting challenge. As outlined in Figure 1 , the elucidation of the specific functional effects of genetic variants discovered in GWAS depends on the creative integration of information from multiple sources, including the ability to utilize human cells of defined genotype as a complement to studies in murine systems. It is not unreasonable to hope that this can lead to the development of new diagnostics and therapeutics that can be tied to personalized information about likely disease outcomes. The report of Lee et al. is a compelling example of how the understanding of human genetics and fundamental cell biology can be brought to bear on an important clinical problem, with the implication that FOXO genes may hold secrets not only of a long life, but also of a good one. An integrative analytic approach that utilizes data from GWAS and clinical outcomes along with work in human monocytes and mouse models has revealed that differences in FOXO3 levels alter the balance of proinflammatory (TNF) versus anti-inflammatory (IL10) cytokine production. This influences the outcome of various diseases that are either exacerbated or ameliorated by these inflammatory responses.
